Payment overview · 2025
General Payments
$2,650.61
87 reported records · 23 companies
Healthcare provider profile · identity verified
Than Luu, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALHAMBRA, CA · NPI 1750548640
Verified facts
What the public records show
CMS Open Payments records show Than Luu, MD received $2,650.61 in general payments during 2025 across 87 reported records.
Phathom Pharmaceuticals, Inc. accounted for 14.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cequa, Creon, Horizant, Jardiance, Kerendia, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 273 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Horizant by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Rybelsus by this doctor in 2024.
SUN PHARMACEUTICAL INDUSTRIES INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cequa as an associated drug or biological on 25765 records involving 9461 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Cequa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $392.58 | 14.8% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $276.65 | 10.4% | 8 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $271.74 | 10.2% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $262.07 | 9.9% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $227.06 | 8.6% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $200.09 | 7.5% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $162.61 | 6.1% | 13 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $150.00 | 5.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.99 | 4.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $94.21 | 3.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.14 | 2.9% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $69.83 | 2.6% | 3 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $69.70 | 2.6% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.89 | 1.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.78 | 1.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $34.88 | 1.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.91 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.96 | 0.9% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.95 | 0.9% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $18.82 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.57 | 0.7% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $16.50 | 0.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $13.68 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,650.61 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $392.58 | 6 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $271.74 | 7 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $262.07 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $227.06 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $185.57 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $168.23 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $155.47 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $154.82 | 7 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $77.24 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $77.24 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.14 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $69.83 | 3 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $69.70 | 3 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $69.70 | 3 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $69.70 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $48.89 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $48.78 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.86 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Cequa cequa |
2025 | Cequa | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 106 | exact normalized | Medicare Part D |
| HORIZANT horizant |
2025 | Horizant | 2024 | 73 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 60 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 193 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 223 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
106 | 38 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
223 | 55 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
30 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
273 | 55 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
193 | 39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
77 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| SUN PHARMACEUTICAL INDUSTRIES INC. Exact reporting entity; no affiliate inference |
2025 | Cequa open payments reported associated product |
CMS Open Payments — General Payments 25765 supporting records · 9461 recipient NPIs · example record 1250962431 |
Cequa · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 797 | 190 |
| Atorvastatin Calcium | Atorvastatin Calcium | 672 | 139 |
| Montelukast Sodium | Montelukast Sodium | 632 | 204 |
| Losartan Potassium | Losartan Potassium | 603 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 439 | 118 |
| Azelastine Hcl | Azelastine Hcl | 381 | 107 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 345 | 107 |
| Gabapentin | Gabapentin | 305 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 291 | 72 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 286 | 75 |
| Diclofenac Sodium | Diclofenac Sodium | 275 | 110 |
| Farxiga | Dapagliflozin Propanediol | 273 | 55 |
| Celecoxib | Celecoxib | 268 | 94 |
| Metformin Hcl | Metformin Hcl | 256 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 238 | 60 |
| Omeprazole | Omeprazole | 232 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 74 |
| Linzess | Linaclotide | 223 | 55 |
| Simvastatin | Simvastatin | 220 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 200 | 66 |
| Nifedipine Er | Nifedipine | 199 | 47 |
| Kerendia | Finerenone | 193 | 39 |
| Amoxicillin | Amoxicillin | 183 | 112 |
| Azithromycin | Azithromycin | 167 | 118 |
| Vascepa | Icosapent Ethyl | 164 | 36 |
| Januvia | Sitagliptin Phosphate | 160 | 33 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 160 | 52 |
| Atenolol | Atenolol | 155 | 35 |
| Fluocinonide | Fluocinonide | 147 | 48 |
| Famotidine | Famotidine | 146 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 146 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 29 |
| Cyclosporine | Cyclosporine | 128 | 57 |
| Allopurinol | Allopurinol | 120 | 40 |
| Hydrocortisone | Hydrocortisone | 115 | 55 |
| Dapagliflozin | Dapagliflozin Propanediol | 114 | 29 |
| Creon | Lipase/Protease/Amylase | 106 | 38 |
| Diclofenac Epolamine | Diclofenac Epolamine | 104 | 28 |
| Glimepiride | Glimepiride | 102 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 99 | 28 |
| Loperamide | Loperamide Hcl | 99 | 70 |
| Fenofibrate | Fenofibrate | 98 | 18 |
| Alendronate Sodium | Alendronate Sodium | 97 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 97 | 22 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 94 | 24 |
| Dexlansoprazole Dr | Dexlansoprazole | 91 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 23 |
| Prednisone | Prednisone | 86 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 32 |
| Lidocaine | Lidocaine | 82 | 21 |
| Rybelsus | Semaglutide | 82 | 17 |
| Amantadine | Amantadine Hcl | 77 | 39 |
| Fenofibrate | Fenofibrate Nanocrystallized | 77 | 19 |
| Vemlidy | Tenofovir Alafenamide | 77 | 11 |
| Meclizine Hcl | Meclizine Hcl | 74 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 20 |
| Horizant | Gabapentin Enacarbil | 73 | 14 |
| Lisinopril | Lisinopril | 69 | 17 |
| Colchicine | Colchicine | 67 | 18 |
| Carvedilol | Carvedilol | 65 | 16 |
| Baclofen | Baclofen | 64 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 64 | 15 |
| Cefdinir | Cefdinir | 63 | 50 |
| Trazodone Hcl | Trazodone Hcl | 63 | 19 |
| Finasteride | Finasteride | 62 | 15 |
| Levofloxacin | Levofloxacin | 61 | 52 |
| Myrbetriq | Mirabegron | 61 | 13 |
| Jardiance | Empagliflozin | 60 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 58 | 31 |
| Clobetasol Propionate | Clobetasol Propionate | 58 | 27 |
| Cequa | Cyclosporine | 56 | suppressed |
| Ranolazine Er | Ranolazine | 56 | 11 |
| Tramadol Hcl | Tramadol Hcl | 56 | 15 |
| Clonidine Hcl | Clonidine Hcl | 54 | 18 |
| Febuxostat | Febuxostat | 54 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 54 | 17 |
| Licart | Diclofenac Epolamine | 53 | 21 |
| Donepezil Hcl | Donepezil Hcl | 52 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | 11 |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Furosemide | Furosemide | 47 | 20 |
| Lactulose | Lactulose | 47 | 13 |
| Metformin Hcl Er | Metformin Hcl | 47 | 19 |
| Restasis | Cyclosporine | 46 | 13 |
| Ztlido | Lidocaine | 46 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 45 | 32 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 45 | 25 |
| Cephalexin | Cephalexin | 43 | 30 |
| Meloxicam | Meloxicam | 43 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 42 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 40 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 12 |
| Cilostazol | Cilostazol | 39 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 37 | 19 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Dutasteride | Dutasteride | 34 | suppressed |
| Eliquis | Apixaban | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 31 | 17 |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | 11 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Prolia | Denosumab | 30 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | 11 |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 24 | 14 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | 12 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | 12 |
| Tradjenta | Linagliptin | 22 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 18 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Benzonatate | Benzonatate | 16 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 13 |
| Propylthiouracil | Propylthiouracil | 16 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Entecavir | Entecavir | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Repatha Pushtronex | Evolocumab | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,650.61 · 87 records | Phathom Pharmaceuticals, Inc. | AFREZZA, AIRSUPRA, BREZTRI, CREON, Cequa, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, Grastek, HORIZANT, IBSRELA, JARDIANCE, Kerendia, Korlym, LINZESS, Natroba, OTEZLA, Odactra, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, REZDIFFRA, Ragwitek, Spinosad, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, XIFAXAN | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cequa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error